|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
Address1 | 11400 Rockville Pike |
Address2 |
|
City | Rockville |
State | MD |
Zip Code | 20852 |
Country | USA |
3. Principal place of business (if different than line 2)
City |
|
State |
|
Zip Code |
|
Country |
|
|
5. Senate ID# 401104864-12
|
||||||||
|
6. House ID# 440290001
|
TYPE OF REPORT | 8. Year | 2023 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
10. Check if this is a Termination Report | Termination Date |
|
11. No Lobbying Issue Activity |
INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
---|---|---|---|---|---|---|---|---|---|
12. Lobbying | 13. Organizations | ||||||||
INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
Signature | Digitally Signed By: Kelly Corredor |
Date | 4/16/2023 8:04:51 AM |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code ALC
16. Specific lobbying issues
Advocated for increased FY24 funding for HRSA's Addiction Medicine Fellowship Program ($30M)
Advocated for increased FY24 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M)
Joined coalition letters supporting increased FY24 funding for a variety of other SUD-related programs in FY24 at HRSA, SAMHSA, and CDC
Advocated for (S. 644/H.R. 1359) the Modernizing Opioid Treatment Access Act, which would allow specially registered opioid treatment program clinicians and addiction specialist physicians to prescribe methadone for OUD that can be picked up from pharmacies, subject to federal regulation or guidance on supply of methadone for unsupervised use.
Advocated for HR 2400- the Reentry Act, which would allow states to provide Medicaid coverage to eligible individuals up to 30 days prior to release from incarceration
Supported S.971 - Due Process Continuity of Care Act, which would amend title XIX of the Social Security Act to remove the Medicaid coverage exclusion for inmates in custody pending disposition of charges, and for other purposes.
Worked on draft legislation that would provide Medicare coverage for evidence-based residential SUD services
Worked on draft legislation that would make permanent a state plan amendment option related to Medicaid's IMD exclusion
Supported H.R.1502 - Comprehensive Opioid Recovery Centers Reauthorization Act of 2023, in its entirety
Advocated for removal of in-person evaluation requirement in proposed telemedicine rules by the DEA and worked on related draft legislation
Advocated for changes to proposed 42 CFR Part 8 rule governing methadone for opioid use disorder
Provided recommendations for the 2024 biennial national drug control strategy in a letter to the Office of National Drug Control Policy (ONDCP). ASAM suggested inclusion in the 2024 strategy, a call for the decoupling criminal penalties and personal drug use possession, implemented as part of a carefully designed set of public health and legal reforms that include strategic, social investments to strengthen American communities and improve lives.
Opposed proposed changes to the STAR-LRP program in S.462 - the Mental Health Professionals Workforce Shortage Loan Repayment Act of 2023
Joined letter asking Congress to remove a lifetime ban that prevents individuals convicted of a drug felony from receiving Supplemental Nutritional Assistance Program (SNAP) or Temporary Assistance for Needy Families TANF) as part of the next Farm Bill.
Joined letter in support for legislation to make Veterans Health Administration (VHA) facilities fully smoke-free.
Provided comments to the Centers for Medicare and Medicaid Services (CMS) encouraging CMS to address the Medicare Physician Fee Schedule's (MPFS) physician payment methodology challenges in the next release of the MPFS in 2024.
Sent letter to the U.S. Department of Health and Human Services' (HHS) Offices of the Secretary and Civil Rights, and the Substance Abuse and Mental Health Administration (SAMHSA), to provide comments on proposed modifications to 42 CFR Part 2 ("Part 2"), applauding policy efforts to further align Part 2 with the Health Insurance Portability and Accountability Act, recommending that HHS conduct a study of the impact of full alignment with HIPAA on the access, availability, and quality of SUD services, coupled with strengthened HIPAA protections against uses, disclosures, or redisclosures of SUD and other medical records outside the healthcare system, and cautioning the final rule make it clear, on a consistent basis, that Part 2 records may not be used, disclosed, or redisclosed for civil, criminal, administrative, or legislative proceedings against the patient in the absence of a court order or a specific, written patient consent for that purpose.
Submitted comments to the Centers for Medicare and Medicaid Services (CMS) on its proposed rule regarding changes to the Medicare Advantage (MA) program for the 2024 plan year. In the letter, ASAM applauded CMS' proposals to strengthen beneficiaries' access to treatment for opioid use disorder (OUD), including proposals that address MA plans' crippling utilization management (UM) policies. ASAM urged CMS to finalize its proposals that limit the use of prior authorization (PA) to its utility in medical necessity determinations, require MA plans to institute UM review committees, and ensure sufficient training, experience and credentials in addiction care for those involved in the UM review process. ASAM also urged CMS to make additional changes surrounding MA plans' use of PA and recommended CMS finalize, with modifications, its update to MA plan network adequacy requirements to address the needs of people with substance use disorder (SUD).
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS), Drug Enforcement Administration (DEA), Office of Natl Drug Control Policy (NDCP), Substance Abuse & Mental Health Services Administration (SAMHSA), Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Health Resources & Services Administration (HRSA), Food & Drug Administration (FDA)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Kelly |
Corredor |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
Advocated for increased FY24 funding for HRSA's Addiction Medicine Fellowship Program ($30M)
Advocated for increased FY24 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M)
Joined coalition letters supporting increased FY24 funding for a variety of other SUD-related programs in FY24 at HRSA, SAMHSA, and CDC
Advocated for (S. 644/H.R. 1359) the Modernizing Opioid Treatment Access Act, which would allow specially registered opioid treatment program clinicians and addiction specialist physicians to prescribe methadone for OUD that can be picked up from pharmacies, subject to federal regulation or guidance on supply of methadone for unsupervised use.
Advocated for HR 2400- the Reentry Act, which would allow states to provide Medicaid coverage to eligible individuals up to 30 days prior to release from incarceration
Supported S.971 - Due Process Continuity of Care Act, which would amend title XIX of the Social Security Act to remove the Medicaid coverage exclusion for inmates in custody pending disposition of charges, and for other purposes.
Worked on draft legislation that would provide Medicare coverage for evidence-based residential SUD services
Worked on draft legislation that would make permanent a state plan amendment option related to Medicaid's IMD exclusion
Supported H.R.1502 - Comprehensive Opioid Recovery Centers Reauthorization Act of 2023, in its entirety
Advocated for removal of in-person evaluation requirement in proposed telemedicine rules by the DEA and worked on related draft legislation
Advocated for changes to proposed 42 CFR Part 8 rule governing methadone for opioid use disorder
Provided recommendations for the 2024 biennial national drug control strategy in a letter to the Office of National Drug Control Policy (ONDCP). ASAM suggested inclusion in the 2024 strategy, a call for the decoupling criminal penalties and personal drug use possession, implemented as part of a carefully designed set of public health and legal reforms that include strategic, social investments to strengthen American communities and improve lives.
Opposed proposed changes to the STAR-LRP program in S.462 - the Mental Health Professionals Workforce Shortage Loan Repayment Act of 2023
Joined letter asking Congress to remove a lifetime ban that prevents individuals convicted of a drug felony from receiving Supplemental Nutritional Assistance Program (SNAP) or Temporary Assistance for Needy Families TANF) as part of the next Farm Bill.
Joined letter in support for legislation to make Veterans Health Administration (VHA) facilities fully smoke-free.
Provided comments to the Centers for Medicare and Medicaid Services (CMS) encouraging CMS to address the Medicare Physician Fee Schedule's (MPFS) physician payment methodology challenges in the next release of the MPFS in 2024.
Sent letter to the U.S. Department of Health and Human Services' (HHS) Offices of the Secretary and Civil Rights, and the Substance Abuse and Mental Health Administration (SAMHSA), to provide comments on proposed modifications to 42 CFR Part 2 ("Part 2"), applauding policy efforts to further align Part 2 with the Health Insurance Portability and Accountability Act, recommending that HHS conduct a study of the impact of full alignment with HIPAA on the access, availability, and quality of SUD services, coupled with strengthened HIPAA protections against uses, disclosures, or redisclosures of SUD and other medical records outside the healthcare system, and cautioning the final rule make it clear, on a consistent basis, that Part 2 records may not be used, disclosed, or redisclosed for civil, criminal, administrative, or legislative proceedings against the patient in the absence of a court order or a specific, written patient consent for that purpose.
Submitted comments to the Centers for Medicare and Medicaid Services (CMS) on its proposed rule regarding changes to the Medicare Advantage (MA) program for the 2024 plan year. In the letter, ASAM applauded CMS' proposals to strengthen beneficiaries' access to treatment for opioid use disorder (OUD), including proposals that address MA plans' crippling utilization management (UM) policies. ASAM urged CMS to finalize its proposals that limit the use of prior authorization (PA) to its utility in medical necessity determinations, require MA plans to institute UM review committees, and ensure sufficient training, experience and credentials in addiction care for those involved in the UM review process. ASAM also urged CMS to make additional changes surrounding MA plans' use of PA and recommended CMS finalize, with modifications, its update to MA plan network adequacy requirements to address the needs of people with substance use disorder (SUD).
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS), Drug Enforcement Administration (DEA), Office of Natl Drug Control Policy (NDCP), Centers For Medicare and Medicaid Services (CMS), Substance Abuse & Mental Health Services Administration (SAMHSA), Congressional Budget Office (CBO), Health Resources & Services Administration (HRSA), Food & Drug Administration (FDA)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Kelly |
Corredor |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MED
16. Specific lobbying issues
Advocated for increased FY24 funding for HRSA's Addiction Medicine Fellowship Program ($30M)
Advocated for increased FY24 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M)
Joined coalition letters supporting increased FY24 funding for a variety of other SUD-related programs in FY24 at HRSA, SAMHSA, and CDC
Advocated for (S. 644/H.R. 1359) the Modernizing Opioid Treatment Access Act, which would allow specially registered opioid treatment program clinicians and addiction specialist physicians to prescribe methadone for OUD that can be picked up from pharmacies, subject to federal regulation or guidance on supply of methadone for unsupervised use.
Advocated for HR 2400- the Reentry Act, which would allow states to provide Medicaid coverage to eligible individuals up to 30 days prior to release from incarceration
Supported S.971 - Due Process Continuity of Care Act, which would amend title XIX of the Social Security Act to remove the Medicaid coverage exclusion for inmates in custody pending disposition of charges, and for other purposes.
Worked on draft legislation that would provide Medicare coverage for evidence-based residential SUD services
Worked on draft legislation that would make permanent a state plan amendment option related to Medicaid's IMD exclusion
Supported H.R.1502 - Comprehensive Opioid Recovery Centers Reauthorization Act of 2023, in its entirety
Advocated for removal of in-person evaluation requirement in proposed telemedicine rules by the DEA and worked on related draft legislation
Advocated for changes to proposed 42 CFR Part 8 rule governing methadone for opioid use disorder
Provided recommendations for the 2024 biennial national drug control strategy in a letter to the Office of National Drug Control Policy (ONDCP). ASAM suggested inclusion in the 2024 strategy, a call for the decoupling criminal penalties and personal drug use possession, implemented as part of a carefully designed set of public health and legal reforms that include strategic, social investments to strengthen American communities and improve lives.
Opposed proposed changes to the STAR-LRP program in S.462 - the Mental Health Professionals Workforce Shortage Loan Repayment Act of 2023
Joined letter asking Congress to remove a lifetime ban that prevents individuals convicted of a drug felony from receiving Supplemental Nutritional Assistance Program (SNAP) or Temporary Assistance for Needy Families TANF) as part of the next Farm Bill.
Joined letter in support for legislation to make Veterans Health Administration (VHA) facilities fully smoke-free.
Provided comments to the Centers for Medicare and Medicaid Services (CMS) encouraging CMS to address the Medicare Physician Fee Schedule's (MPFS) physician payment methodology challenges in the next release of the MPFS in 2024.
Sent letter to the U.S. Department of Health and Human Services' (HHS) Offices of the Secretary and Civil Rights, and the Substance Abuse and Mental Health Administration (SAMHSA), to provide comments on proposed modifications to 42 CFR Part 2 ("Part 2"), applauding policy efforts to further align Part 2 with the Health Insurance Portability and Accountability Act, recommending that HHS conduct a study of the impact of full alignment with HIPAA on the access, availability, and quality of SUD services, coupled with strengthened HIPAA protections against uses, disclosures, or redisclosures of SUD and other medical records outside the healthcare system, and cautioning the final rule make it clear, on a consistent basis, that Part 2 records may not be used, disclosed, or redisclosed for civil, criminal, administrative, or legislative proceedings against the patient in the absence of a court order or a specific, written patient consent for that purpose.
Submitted comments to the Centers for Medicare and Medicaid Services (CMS) on its proposed rule regarding changes to the Medicare Advantage (MA) program for the 2024 plan year. In the letter, ASAM applauded CMS' proposals to strengthen beneficiaries' access to treatment for opioid use disorder (OUD), including proposals that address MA plans' crippling utilization management (UM) policies. ASAM urged CMS to finalize its proposals that limit the use of prior authorization (PA) to its utility in medical necessity determinations, require MA plans to institute UM review committees, and ensure sufficient training, experience and credentials in addiction care for those involved in the UM review process. ASAM also urged CMS to make additional changes surrounding MA plans' use of PA and recommended CMS finalize, with modifications, its update to MA plan network adequacy requirements to address the needs of people with substance use disorder (SUD).
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS), Office of Natl Drug Control Policy (NDCP), Centers For Medicare and Medicaid Services (CMS), Drug Enforcement Administration (DEA), Substance Abuse & Mental Health Services Administration (SAMHSA), Congressional Budget Office (CBO), Health Resources & Services Administration (HRSA), Food & Drug Administration (FDA)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Kelly |
Corredor |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
Advocated for increased FY24 funding for HRSA's Addiction Medicine Fellowship Program ($30M)
Advocated for increased FY24 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M)
Joined coalition letters supporting increased FY24 funding for a variety of other SUD-related programs in FY24 at HRSA, SAMHSA, and CDC
Advocated for (S. 644/H.R. 1359) the Modernizing Opioid Treatment Access Act, which would allow specially registered opioid treatment program clinicians and addiction specialist physicians to prescribe methadone for OUD that can be picked up from pharmacies, subject to federal regulation or guidance on supply of methadone for unsupervised use.
Advocated for HR 2400- the Reentry Act, which would allow states to provide Medicaid coverage to eligible individuals up to 30 days prior to release from incarceration
Supported S.971 - Due Process Continuity of Care Act, which would amend title XIX of the Social Security Act to remove the Medicaid coverage exclusion for inmates in custody pending disposition of charges, and for other purposes.
Worked on draft legislation that would provide Medicare coverage for evidence-based residential SUD services
Worked on draft legislation that would make permanent a state plan amendment option related to Medicaid's IMD exclusion
Supported H.R.1502 - Comprehensive Opioid Recovery Centers Reauthorization Act of 2023, in its entirety
Advocated for removal of in-person evaluation requirement in proposed telemedicine rules by the DEA and worked on related draft legislation
Advocated for changes to proposed 42 CFR Part 8 rule governing methadone for opioid use disorder
Provided recommendations for the 2024 biennial national drug control strategy in a letter to the Office of National Drug Control Policy (ONDCP). ASAM suggested inclusion in the 2024 strategy, a call for the decoupling criminal penalties and personal drug use possession, implemented as part of a carefully designed set of public health and legal reforms that include strategic, social investments to strengthen American communities and improve lives.
Opposed proposed changes to the STAR-LRP program in S.462 - the Mental Health Professionals Workforce Shortage Loan Repayment Act of 2023
Joined letter asking Congress to remove a lifetime ban that prevents individuals convicted of a drug felony from receiving Supplemental Nutritional Assistance Program (SNAP) or Temporary Assistance for Needy Families TANF) as part of the next Farm Bill.
Joined letter in support for legislation to make Veterans Health Administration (VHA) facilities fully smoke-free.
Provided comments to the Centers for Medicare and Medicaid Services (CMS) encouraging CMS to address the Medicare Physician Fee Schedule's (MPFS) physician payment methodology challenges in the next release of the MPFS in 2024.
Sent letter to the U.S. Department of Health and Human Services' (HHS) Offices of the Secretary and Civil Rights, and the Substance Abuse and Mental Health Administration (SAMHSA), to provide comments on proposed modifications to 42 CFR Part 2 ("Part 2"), applauding policy efforts to further align Part 2 with the Health Insurance Portability and Accountability Act, recommending that HHS conduct a study of the impact of full alignment with HIPAA on the access, availability, and quality of SUD services, coupled with strengthened HIPAA protections against uses, disclosures, or redisclosures of SUD and other medical records outside the healthcare system, and cautioning the final rule make it clear, on a consistent basis, that Part 2 records may not be used, disclosed, or redisclosed for civil, criminal, administrative, or legislative proceedings against the patient in the absence of a court order or a specific, written patient consent for that purpose.
Submitted comments to the Centers for Medicare and Medicaid Services (CMS) on its proposed rule regarding changes to the Medicare Advantage (MA) program for the 2024 plan year. In the letter, ASAM applauded CMS' proposals to strengthen beneficiaries' access to treatment for opioid use disorder (OUD), including proposals that address MA plans' crippling utilization management (UM) policies. ASAM urged CMS to finalize its proposals that limit the use of prior authorization (PA) to its utility in medical necessity determinations, require MA plans to institute UM review committees, and ensure sufficient training, experience and credentials in addiction care for those involved in the UM review process. ASAM also urged CMS to make additional changes surrounding MA plans' use of PA and recommended CMS finalize, with modifications, its update to MA plan network adequacy requirements to address the needs of people with substance use disorder (SUD).
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS), Office of Natl Drug Control Policy (NDCP), Centers For Medicare and Medicaid Services (CMS), Drug Enforcement Administration (DEA), Substance Abuse & Mental Health Services Administration (SAMHSA), Congressional Budget Office (CBO), Food & Drug Administration (FDA), Health Resources & Services Administration (HRSA)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Kelly |
Corredor |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code BUD
16. Specific lobbying issues
Advocated for increased FY24 funding for HRSA's Addiction Medicine Fellowship Program ($30M)
Advocated for increased FY24 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M)
Joined coalition letters supporting increased FY24 funding for a variety of other SUD-related programs in FY24 at HRSA, SAMHSA, and CDC
Advocated for (S. 644/H.R. 1359) the Modernizing Opioid Treatment Access Act, which would allow specially registered opioid treatment program clinicians and addiction specialist physicians to prescribe methadone for OUD that can be picked up from pharmacies, subject to federal regulation or guidance on supply of methadone for unsupervised use.
Advocated for HR 2400- the Reentry Act, which would allow states to provide Medicaid coverage to eligible individuals up to 30 days prior to release from incarceration
Supported S.971 - Due Process Continuity of Care Act, which would amend title XIX of the Social Security Act to remove the Medicaid coverage exclusion for inmates in custody pending disposition of charges, and for other purposes.
Worked on draft legislation that would provide Medicare coverage for evidence-based residential SUD services
Worked on draft legislation that would make permanent a state plan amendment option related to Medicaid's IMD exclusion
Supported H.R.1502 - Comprehensive Opioid Recovery Centers Reauthorization Act of 2023, in its entirety
Advocated for removal of in-person evaluation requirement in proposed telemedicine rules by the DEA and worked on related draft legislation
Advocated for changes to proposed 42 CFR Part 8 rule governing methadone for opioid use disorder
Provided recommendations for the 2024 biennial national drug control strategy in a letter to the Office of National Drug Control Policy (ONDCP). ASAM suggested inclusion in the 2024 strategy, a call for the decoupling criminal penalties and personal drug use possession, implemented as part of a carefully designed set of public health and legal reforms that include strategic, social investments to strengthen American communities and improve lives.
Opposed proposed changes to the STAR-LRP program in S.462 - the Mental Health Professionals Workforce Shortage Loan Repayment Act of 2023
Joined letter asking Congress to remove a lifetime ban that prevents individuals convicted of a drug felony from receiving Supplemental Nutritional Assistance Program (SNAP) or Temporary Assistance for Needy Families TANF) as part of the next Farm Bill.
Joined letter in support for legislation to make Veterans Health Administration (VHA) facilities fully smoke-free.
Provided comments to the Centers for Medicare and Medicaid Services (CMS) encouraging CMS to address the Medicare Physician Fee Schedule's (MPFS) physician payment methodology challenges in the next release of the MPFS in 2024.
Sent letter to the U.S. Department of Health and Human Services' (HHS) Offices of the Secretary and Civil Rights, and the Substance Abuse and Mental Health Administration (SAMHSA), to provide comments on proposed modifications to 42 CFR Part 2 ("Part 2"), applauding policy efforts to further align Part 2 with the Health Insurance Portability and Accountability Act, recommending that HHS conduct a study of the impact of full alignment with HIPAA on the access, availability, and quality of SUD services, coupled with strengthened HIPAA protections against uses, disclosures, or redisclosures of SUD and other medical records outside the healthcare system, and cautioning the final rule make it clear, on a consistent basis, that Part 2 records may not be used, disclosed, or redisclosed for civil, criminal, administrative, or legislative proceedings against the patient in the absence of a court order or a specific, written patient consent for that purpose.
Submitted comments to the Centers for Medicare and Medicaid Services (CMS) on its proposed rule regarding changes to the Medicare Advantage (MA) program for the 2024 plan year. In the letter, ASAM applauded CMS' proposals to strengthen beneficiaries' access to treatment for opioid use disorder (OUD), including proposals that address MA plans' crippling utilization management (UM) policies. ASAM urged CMS to finalize its proposals that limit the use of prior authorization (PA) to its utility in medical necessity determinations, require MA plans to institute UM review committees, and ensure sufficient training, experience and credentials in addiction care for those involved in the UM review process. ASAM also urged CMS to make additional changes surrounding MA plans' use of PA and recommended CMS finalize, with modifications, its update to MA plan network adequacy requirements to address the needs of people with substance use disorder (SUD).
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS), Office of Natl Drug Control Policy (NDCP), Substance Abuse & Mental Health Services Administration (SAMHSA), Centers For Medicare and Medicaid Services (CMS), Drug Enforcement Administration (DEA), Congressional Budget Office (CBO), Health Resources & Services Administration (HRSA), Food & Drug Administration (FDA)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Kelly |
Corredor |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code INS
16. Specific lobbying issues
Advocated for increased FY24 funding for HRSA's Addiction Medicine Fellowship Program ($30M)
Advocated for increased FY24 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M)
Joined coalition letters supporting increased FY24 funding for a variety of other SUD-related programs in FY24 at HRSA, SAMHSA, and CDC
Advocated for (S. 644/H.R. 1359) the Modernizing Opioid Treatment Access Act, which would allow specially registered opioid treatment program clinicians and addiction specialist physicians to prescribe methadone for OUD that can be picked up from pharmacies, subject to federal regulation or guidance on supply of methadone for unsupervised use.
Advocated for HR 2400- the Reentry Act, which would allow states to provide Medicaid coverage to eligible individuals up to 30 days prior to release from incarceration
Supported S.971 - Due Process Continuity of Care Act, which would amend title XIX of the Social Security Act to remove the Medicaid coverage exclusion for inmates in custody pending disposition of charges, and for other purposes.
Worked on draft legislation that would provide Medicare coverage for evidence-based residential SUD services
Worked on draft legislation that would make permanent a state plan amendment option related to Medicaid's IMD exclusion
Supported H.R.1502 - Comprehensive Opioid Recovery Centers Reauthorization Act of 2023, in its entirety
Advocated for removal of in-person evaluation requirement in proposed telemedicine rules by the DEA and worked on related draft legislation
Advocated for changes to proposed 42 CFR Part 8 rule governing methadone for opioid use disorder
Provided recommendations for the 2024 biennial national drug control strategy in a letter to the Office of National Drug Control Policy (ONDCP). ASAM suggested inclusion in the 2024 strategy, a call for the decoupling criminal penalties and personal drug use possession, implemented as part of a carefully designed set of public health and legal reforms that include strategic, social investments to strengthen American communities and improve lives.
Opposed proposed changes to the STAR-LRP program in S.462 - the Mental Health Professionals Workforce Shortage Loan Repayment Act of 2023
Joined letter asking Congress to remove a lifetime ban that prevents individuals convicted of a drug felony from receiving Supplemental Nutritional Assistance Program (SNAP) or Temporary Assistance for Needy Families TANF) as part of the next Farm Bill.
Joined letter in support for legislation to make Veterans Health Administration (VHA) facilities fully smoke-free.
Provided comments to the Centers for Medicare and Medicaid Services (CMS) encouraging CMS to address the Medicare Physician Fee Schedule's (MPFS) physician payment methodology challenges in the next release of the MPFS in 2024.
Sent letter to the U.S. Department of Health and Human Services' (HHS) Offices of the Secretary and Civil Rights, and the Substance Abuse and Mental Health Administration (SAMHSA), to provide comments on proposed modifications to 42 CFR Part 2 ("Part 2"), applauding policy efforts to further align Part 2 with the Health Insurance Portability and Accountability Act, recommending that HHS conduct a study of the impact of full alignment with HIPAA on the access, availability, and quality of SUD services, coupled with strengthened HIPAA protections against uses, disclosures, or redisclosures of SUD and other medical records outside the healthcare system, and cautioning the final rule make it clear, on a consistent basis, that Part 2 records may not be used, disclosed, or redisclosed for civil, criminal, administrative, or legislative proceedings against the patient in the absence of a court order or a specific, written patient consent for that purpose.
Submitted comments to the Centers for Medicare and Medicaid Services (CMS) on its proposed rule regarding changes to the Medicare Advantage (MA) program for the 2024 plan year. In the letter, ASAM applauded CMS' proposals to strengthen beneficiaries' access to treatment for opioid use disorder (OUD), including proposals that address MA plans' crippling utilization management (UM) policies. ASAM urged CMS to finalize its proposals that limit the use of prior authorization (PA) to its utility in medical necessity determinations, require MA plans to institute UM review committees, and ensure sufficient training, experience and credentials in addiction care for those involved in the UM review process. ASAM also urged CMS to make additional changes surrounding MA plans' use of PA and recommended CMS finalize, with modifications, its update to MA plan network adequacy requirements to address the needs of people with substance use disorder (SUD).
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS), Office of Natl Drug Control Policy (NDCP), Centers For Medicare and Medicaid Services (CMS), Drug Enforcement Administration (DEA), Substance Abuse & Mental Health Services Administration (SAMHSA), Congressional Budget Office (CBO), Health Resources & Services Administration (HRSA), Food & Drug Administration (FDA)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Kelly |
Corredor |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
Address |
|
||||||
City |
|
State |
|
Zip Code |
|
Country |
|
21. Client new principal place of business (if different than line 20)
City |
|
State |
|
Zip Code |
|
Country |
|
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
1 |
|
3 |
|
||||||
2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% |
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
1 | 3 | 5 |
2 | 4 | 6 |
CONVICTIONS DISCLOSURE
29. Have any of the lobbyists listed on this report been convicted in a Federal or State Court of an offense involving bribery,
extortion, embezzlement, an illegal kickback, tax evasion, fraud, a conflict of interest, making a false statement, perjury, or money laundering?
Lobbyist Name | Description of Offense(s) |